Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.

Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.

Daiichi Sankyo denies report it is in negotiations to sell its OTC business, but might such a move actually align well with mid-term strategy?

Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.